Skip to main content
Back to Trials
NCT07840326PHASE2Recruiting

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

Sundance Biosciences, Inc.

Start Date

10/1/2026

Completion Date

7/1/2027

Summary

The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.

Detailed Description

This Phase 2a, randomized, double-blind, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and impact on measures of neuroinflammation in the central nervous system (CNS) of SUN-627 administered at 2 dose levels in participants with non-active SPMS/PPMS.

Eligibility Criteria

Age Range: 18 years to 70 years

Inclusion Criteria: 1. Aged 18-70, inclusive 2. Diagnosis of PPMS or non-active SPMS 3. No MS relapses in the past 2 years 4. Evidence that MS has continued to get worse over time 5. A level of disability that fits the study requirements Exclusion Criteria: 1. Use of certain medications or treatments before the study, or need for these treatments during the study 2. Current participation in another research study 3. Certain abnormal heart rhythm findings on ECG or other heart conditions that may increase risk 4. Certain serious or unstable medical conditions that could make the study unsafe 5. Active infection, recent infection, or a history of repeated infections Additional inclusion and exclusion criteria are outlined in the full study protocol.

Interventions

DRUG

SUN-627

OTHER

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Primary Progressive Multiple SclerosisPrimary Progressive MSPrimary Progressive Multiple Sclerosis (PPMS)Secondary Progressive MS (SPMS)Secondary Progressive Multiple Sclerosis (SPMS)Secondary Progressive MSNon-Active SPMSNon-Active Secondary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis With Inflammatory Disease Activity

Locations

Local Institution - Site 102

Atlanta, Georgia 30309

United States

Local Institution - Site 101

Raleigh, North Carolina 27607

United States

Local Institution - Site 104

Columbus, Ohio 43235

United States